Abstract
The paper deals with the possibilities of treatment of gastrointestinal stromal tumor - one of the first solid tumors where chemotherapy was almost completely pushed out targeted biological therapy. The primary targeted therapy in advanced inoperable gastrointestinal stromal tumor is imatinib mesylate.
In addition to a review of clinical studies and therapeutic results corresponding article on controversial issues - initial dose of imatinib, predictive factors, which may soon lead to a primary standard dose escalation, the question of continuing treatment after achieving complete remission. Furthermore, the article points out other possibilities continue targeted biological therapy after failure of imatinib - the use of sunitinib, nilotinib, prospectively IPI-504th The conclusion summarizes the basic experience in the treatment of GIST in the workplace author - FN Motol.